Annex 1 Webinar

Annex 1: Interpretation and Implementation of the latest revision



Insight from Industry Experts - Understanding and applying aspects of Annex 1 revision

Thursday 11th March 2021 Time: 14:00 – 15:30 (Irish Standard Time)

13:40 – 14:00	Registration & Log in	All Attendees
14:00 – 14:05	Moderator: Welcome & Introduction from PDA	Alan Kelly, Project Engineer, PM Group
14:05 – 14:25	PUPSIT – Consideration of the risk-based approach and potential challenges when implementing PUPSIT and how to overcome them to ensure compliance is achieved. Contamination Control Strategy (CCS) – Discussion of the intended approach to the CCS and how it links-in with other key	Andrew Hopkins, AbbVie, Ex- MHRA Regulator and previous member of Annex 1 working group
14:25 – 14:45	GMP strategies Process simulations – On outline of the key changes and how they can be implemented. Impacts to Biological DS manufacture / Low Bioburden – a	Greg McGurk, Regeneron, Ex- HPRA Regulator and previous member of Annex 1 working group
	walkthrough of how some of the Annex 1 principles are applied in the manufacture of low bioburden products and how compliance should be demonstrated.	
14:45 – 15:05	HPRA Regulatory Status — A status update from the previous consultation and status update regarding Annex 1 revision.	Paul Sexton, HPRA Regulator
15:05 – 15:20	Q&A Session – Alan Kelly, Andrew Hopkins, Greg McGurk, Paul Sexton	
15:20 – 15:25	Fireside Chat — Q&A discussion on how pharmaceutical equipment suppliers can help enable end users comply to Annex 1 revision.	Alan Kelly, Project Engineer, PM Group Alf Gregg, Commercial Director SteriTech Process Solutions
15:25 – 15:30	Closing remarks -	Alan Kelly, Project Engineer, PM Group

MAIN SPONSOR













REGISTER on https://www.eventbrite.ie/e/annex-1-interpretation-and-implementation-of-the-latest-revision-tickets-

138762463263 : or contact Richard.O'Connor@sanofi.com

PDA members: 90 euros, non-members: 150 euros (plus booking fee)